CUMBERLAND PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cumberland Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q2 2024.
  • Cumberland Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$1.09M, a 224% decline year-over-year.
  • Cumberland Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$10.4M, a 481% decline year-over-year.
  • Cumberland Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$6.28M, a 12.7% decline from 2022.
  • Cumberland Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$5.57M, a 58.8% decline from 2021.
  • Cumberland Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$3.51M, a 5.04% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$10.4M -$1.09M -$1.96M -224% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$8.42M -$1.95M -$2.14M -1113% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$6.28M -$6.29M -$3.85M -158% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$2.43M -$1.05M -$641K -157% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-13
Q2 2023 -$1.78M $872K +$2.21M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$3.99M $192K +$1.58M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$5.57M -$2.44M +$1.41M +36.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$6.98M -$409K +$647K +61.3% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-13
Q2 2022 -$7.62M -$1.34M -$2.56M -209% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-13
Q1 2022 -$5.06M -$1.39M -$1.55M -930% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-13
Q4 2021 -$3.51M -$3.85M -$2.96M -335% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-13
Q3 2021 -$544K -$1.06M -$574K -119% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-13
Q2 2021 $29.9K $1.23M +$2.15M Apr 1, 2021 Jun 30, 2021 10-K 2023-03-13
Q1 2021 -$2.12M $167K +$1.22M Jan 1, 2021 Mar 31, 2021 10-K 2023-03-13
Q4 2020 -$3.34M -$884K +$76.9K +8.01% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$3.42M -$482K +$1.47M +75.3% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-11
Q2 2020 -$4.89M -$918K -$369K -67.1% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-11
Q1 2020 -$4.52M -$1.06M -$982K -1329% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-11
Q4 2019 -$3.54M -$961K +$1.26M +56.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$4.8M -$1.95M -$311K -18.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-12
Q2 2019 -$4.49M -$550K +$171K +23.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-12
Q1 2019 -$4.66M -$73.9K +$2.31M +96.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-12
Q4 2018 -$6.96M -$2.22M -$1.42M -177% Oct 1, 2018 Dec 31, 2018 8-K 2020-12-10
Q3 2018 -$5.54M -$1.64M -$900K -121% Jul 1, 2018 Sep 30, 2018 8-K 2020-12-10
Q2 2018 -$4.64M -$721K +$4.44M +86% Apr 1, 2018 Jun 30, 2018 8-K 2020-12-10
Q1 2018 -$9.08M -$2.38M -$1.1M -86.7% Jan 1, 2018 Mar 31, 2018 8-K 2020-12-10
Q4 2017 -$7.98M -$801K -$50.9K -6.78% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$7.93M -$743K -$849K -800% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$7.08M -$5.16M -$5.11M -10641% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$1.97M -$1.27M -$1.02M -404% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$945K -$750K -$901K -596% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-09
Q3 2016 -$43.9K $106K -$20.4K -16.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-09
Q2 2016 -$23.5K -$48K -$455K -112% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-09
Q1 2016 $432K -$253K -$299K -647% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-09
Q4 2015 $731K $151K -$518K -77.4% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-13
Q3 2015 $1.25M $127K -$619K -83% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-13
Q2 2015 $1.87M $407K -$315K -43.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-13
Q1 2015 $2.18M $46.3K -$240K -83.8% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-13
Q4 2014 $2.42M $669K +$2.17M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 $254K $746K +$1.57M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$1.31M $723K +$1.36M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$2.67M $286K -$568K -66.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
Q4 2013 -$2.1M -$1.5M -$3.31M -183% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-09
Q3 2013 $1.2M -$820K -$2.69M -144% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-09
Q2 2013 $3.89M -$639K -$2.38M -137% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-09
Q1 2013 $6.27M $855K +$432K +102% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-09
Q4 2012 $5.84M $1.81M +$894K +98% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-11
Q3 2012 $4.95M $1.87M +$22.1K +1.2% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-11
Q2 2012 $4.93M $1.74M -$433K -19.9% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-11
Q1 2012 $5.36M $423K -$298K -41.3% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-11
Q4 2011 $5.66M $912K Oct 1, 2011 Dec 31, 2011 10-K 2013-03-12
Q3 2011 $1.85M +$839K +83.2% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-12
Q2 2011 $2.18M +$1.89M +658% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-12
Q1 2011 $721K Jan 1, 2011 Mar 31, 2011 10-K 2013-03-12
Q3 2010 $1.01M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 $287K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.